详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

High PD-L1 level of advanced hepatic lymphoepithelioma-like carcinoma response favorably to lenvatinib plus toripalimab.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. [2]Department of Radiotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. [3]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. [4]West China Medical School, Sichuan University, Chengdu, China. [5]Department of Abdominal Cancer, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.

出处：

DOI：

ISSN：

摘要：

Lymphoepithelioma-like carcinoma (LELC) is an uncommon subtype of primary liver cancer with predominant lymphocyte infiltration and a relatively favorable outcome. However, no standard treatment for advanced hepatic LELC has been established. Here, we give a first report of a 60-year-old man with advanced hepatic LELC who had a high expression of PD-L1 in tumor cells and a high level of tumor-infiltrating leukocytes (TILs) in the tumor microenvironment (TME). After receiving six cycles of multiple receptor tyrosine kinase inhibitor (rTKI) with lenvatinib plus PD-1 inhibitor toripalimab treatment, the patient achieved persistent partial response (PR). Our report indicates that advanced hepatic LELC with high expression of PD-L1 may benefit from the combination of rTKI and PD-L1/PD-1 blockade. Therefore, this potential strategy should be considered when treating those rare liver cancers.© 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 2 区医学

小类 | 2 区肿瘤学

最新[2023]版：

大类 | 2 区

医学

小类 | 2 区肿瘤学

第一作者：

第一作者机构： [1]Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.

共同第一作者：

通讯作者：

通讯机构： [2]Department of Radiotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. [5]Department of Abdominal Cancer, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. [*1]Department of Radiotherapy and Abdominal Cancer, Cancer Center, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu 610041, Sichuan Province, China. [*2]Department of Abdominal Cancer, Cancer Center, West China Hospital, Sichuan University, No. 37, GuoXue Xiang, Chengdu 610041, Sichuan Province, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：